Published in Hepatology on December 01, 1992
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Cryoglobulins. J Clin Pathol (2002) 1.85
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
HCV in sickle cell disease. J Natl Med Assoc (2003) 1.39
Hepatitis C: progress and problems. Clin Microbiol Rev (1994) 1.37
Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites (2014) 1.19
Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut (1996) 1.17
Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci (2002) 1.06
Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci (1996) 1.06
Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci (1997) 1.04
Erythropoietic and hepatic porphyrias. J Inherit Metab Dis (2000) 1.00
Environmental chemical exposures and disturbances of heme synthesis. Environ Health Perspect (1997) 0.98
Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol (2009) 0.96
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol (2015) 0.90
Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci (1996) 0.87
Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon (2010) 0.85
Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Am J Hum Genet (1998) 0.85
The GOR gene product cannot cross-react with hepatitis C virus in humans. Clin Exp Immunol (2001) 0.82
Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. West J Med (1995) 0.78
An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report. World J Gastroenterol (2007) 0.76
Detection of hepatitis C virus by polymerase chain reaction and recombinant immunoblot assay 3.0 in porphyria cutanea tarda. Hepatology (1995) 0.75
Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda. Clin Exp Immunol (2001) 0.75
Porphyria cutanea tarda and hepatitis C virus infection in a patient with acute liver failure. West J Med (1994) 0.75
Sun, iron, alcohol and intrinsic liver disease: a recipe for failure. BMJ Case Rep (2013) 0.75
Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C. Clin J Gastroenterol (2017) 0.75
Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations. J Gastroenterol (2007) 0.75
Porphyria cutanea tarda and hepatitis G and C virus infection. Eur J Clin Microbiol Infect Dis (1998) 0.75
Glucose-6-phosphate dehydrogenase deficiency. Lancet (2008) 8.26
Prenatal sex determination by DNA amplification from maternal peripheral blood. Lancet (1989) 4.42
Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet (1995) 3.43
Survival and complications in thalassemia. Ann N Y Acad Sci (2005) 2.25
Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet (1983) 2.05
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet (1997) 1.85
Detection of single-copy fetal DNA sequence from maternal blood. Lancet (1990) 1.85
High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology (1998) 1.79
Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab (1999) 1.78
Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost (2010) 1.71
Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. Blood Cells Mol Dis (2008) 1.63
Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis (2004) 1.62
Survival and disease complications in thalassemia major. Ann N Y Acad Sci (1998) 1.62
A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J Viral Hepat (2010) 1.58
Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol (1995) 1.58
cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem (1998) 1.56
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol (2000) 1.56
Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology (2001) 1.53
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 1.47
Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet (1989) 1.42
No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. Hepatology (1996) 1.42
Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology (2000) 1.42
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis (2008) 1.41
Heterogeneity of hemochromatosis in Italy. Gastroenterology (1998) 1.38
Immunochemical estimation of haemoglobin types in red blood cells by FACS analysis. Br J Haematol (1994) 1.38
Hepatitis G virus infection in the elderly. Ital J Gastroenterol Hepatol (1998) 1.37
Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A (2001) 1.34
New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood (2001) 1.33
Association of thalassaemia intermedia with a beta-globin gene haplotype. Br J Haematol (1987) 1.28
[Infectivity of Anopheles melas vis-a-vis Plasmodium falciparum in the coastal lagoon area of Benin]. Bull Soc Pathol Exot (1999) 1.28
Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang (2009) 1.19
JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.19
Variation of HbF and F-cell number with the G-gamma Xmn I (C-T) polymorphism in normal individuals. Blood (1992) 1.18
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology (1992) 1.16
A gene controlling fetal hemoglobin expression in adults is not linked to the non-alpha globin cluster. EMBO J (1983) 1.16
Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet (2000) 1.16
Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am J Hum Genet (1994) 1.15
Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control. Blood (1991) 1.11
The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet (2004) 1.11
Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest (2002) 1.09
High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int (1995) 1.09
Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis (2010) 1.08
The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology (1996) 1.06
Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int (2008) 1.06
Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol Dis (2000) 1.06
Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology (1994) 1.04
New syndrome manifested by mandibular hypoplasia, acroosteolysis, stiff joints and cutaneous atrophy (mandibuloacral dysplasia) in two unrelated boys. Birth Defects Orig Artic Ser (1971) 1.04
Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol (2000) 1.04
Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver (1996) 1.04
Early impairment of large artery structure and function in type I diabetes mellitus. Diabetologia (1999) 1.03
Feasibility of prenatal diagnosis of beta-thalassaemia with synthetic DNA probes in two Mediterranean populations. Lancet (1985) 1.03
Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. Baillieres Best Pract Res Clin Haematol (2000) 1.03
The expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous beta-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. Br J Haematol (1997) 1.02
Pulmonary hypertension in patients with thalassemia major. Am Heart J (1999) 1.01
Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes. Blood (1995) 1.01
Levobupivacaine versus racemic bupivacaine for spinal anaesthesia in orthopaedic major surgery. Minerva Anestesiol (2006) 1.00
Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J (2000) 1.00
Iron overload in porphyria cutanea tarda. Haematologica (1999) 0.99
Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol (1997) 0.99
Effect of sperm morphology and motile sperm count on outcome of intrauterine insemination in oligozoospermia and/or asthenozoospermia. Fertil Steril (1990) 0.98
Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood (2001) 0.98
Coagulation and splenectomy: an overview. Ann N Y Acad Sci (2005) 0.97
Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet (1971) 0.97
Idiopathic haemochromatosis and HLA antigens in Italy: is A3 Bw35 HLA haplotype a marker for idiopathic haemochromatosis gene in north east regions? J Clin Pathol (1986) 0.97
Prenatal sex determination from maternal peripheral blood using the polymerase chain reaction. Hum Genet (1993) 0.97
Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol (2001) 0.96
Thalassemia intermedia. Haematologica (1995) 0.96
Interaction between homozygous beta (0) thalassaemia and the Swiss type of hereditary persistence of fetal haemoglobin. Br J Haematol (1981) 0.96
Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis (2003) 0.95
Factors affecting list size of general practitioners and number of drugs prescribed: findings of a recent study. Soc Sci Med (1983) 0.95